Skip to main
MNKD
MNKD logo

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corp's positive outlook is supported by potential label expansion for its Tyvaso DPI product, which could create new market opportunities and drive revenue growth. The possibility of a broader label, regardless of limitations, is viewed as a significant catalyst for MNKD's stock, particularly due to the ongoing interest in sub-group analyses involving patients with Pulmonary Arterial Hypertension (PAH). Additionally, historical correlations suggest that favorable developments for UTHR, related to Tyvaso, may also positively influence MannKind's stock performance.

Bears say

MannKind Corp's financial outlook is characterized by cautious estimates for its Afrezza product, projecting sales of $127 million by 2030, which may still be considered conservative depending on the success of pediatric market opportunities. Additionally, the valuation of its pipeline products, MNKD-101 and MNKD-201, incorporates low probabilities of success—40% for MNKD-101 and 30% for MNKD-201—indicating significant uncertainty regarding future revenue streams. Collectively, these factors contribute to a negative sentiment regarding the financial stability and growth potential of MannKind Corp.

MannKind (MNKD) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 5 analysts, MannKind (MNKD) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.